The European Investment Bank is putting $23.2M into Tensive, a biomedical company working on biomaterials for regenerative medicine. The financing, announced without a specified round type, targets a field where clinical need remains acute: reconstructive surgery following breast cancer.
Tensive develops advanced biomaterials aimed at improving tissue repair and regeneration in that surgical context. The EIB鈥檚 backing-typically reserved for projects with clear technological and societal impact-signals confidence in the company鈥檚 approach, though details on how the capital will be deployed were not disclosed. For a firm operating in a niche where regulatory hurdles are steep, the injection provides runway to advance its pipeline.





.png&w=3840&q=75)












.png&w=3840&q=75)